Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Other Operating Expenses (2021 - 2026)

bioAffinity Technologies has reported Other Operating Expenses over the past 5 years, most recently at -$2.7 million for Q1 2026.

  • Quarterly Other Operating Expenses fell 79.64% to -$2.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $962901.0 through Mar 2026, down 72.64% year-over-year, with the annual reading at $5.3 million for FY2025, 21.95% down from the prior year.
  • Other Operating Expenses was -$2.7 million for Q1 2026 at bioAffinity Technologies, down from $1.3 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $1.8 million in Q4 2024 and troughed at -$2.7 million in Q1 2026.
  • The 5-year median for Other Operating Expenses is $193600.0 (2023), against an average of $490190.0.
  • Year-over-year, Other Operating Expenses skyrocketed 10351.86% in 2023 and then tumbled 186.3% in 2025.
  • A 5-year view of Other Operating Expenses shows it stood at -$16999.0 in 2022, then skyrocketed by 10351.86% to $1.7 million in 2023, then grew by 3.32% to $1.8 million in 2024, then decreased by 28.85% to $1.3 million in 2025, then crashed by 309.75% to -$2.7 million in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Other Operating Expenses are -$2.7 million (Q1 2026), $1.3 million (Q4 2025), and $1.2 million (Q3 2025).